SEC Filing Analysis: REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director was awarded 8,200 stock options as part of a standard compensation plan, a routine event with minimal market impact.
• Market Impact: Neutral. This is a non-cash compensation grant, not an open-market trade, and is unlikely to influence trading activity.

Company Information

Field	Value
Company	REVIVA PHARMACEUTICALS HOLDINGS, INC.
Ticker Symbol	RVPH
CIK	0001742927
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	SAXENA PARAG
CIK	0001015823
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-12-18
Transaction Code	A (Grant)
Security Type	Stock Option (right to buy)
Shares Involved	8,200
Price Per Share	$0.00
Total Value	$0
Shares Owned After	8,200 (options)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.0%
Shares Transacted	8,200
% of Shares Outstanding	Not Calculable
Post-Transaction Ownership	8,200 options
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction value is $0, making it immaterial against the company's $60 million market capitalization.
• Dilution Impact: The grant introduces 8,200 potential shares. As shares outstanding data is unavailable, the exact dilution percentage cannot be calculated, but the number of shares is small for a company of this size.
• Transaction Significance: The transaction is a routine award of stock options to a director as part of their compensation package. It is not an open-market transaction and does not reflect a new investment decision by the insider. Therefore, its significance is low.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Equity grants to directors are standard practice and are not typically interpreted as a bullish or bearish signal by the market.

Volume & Sentiment

• Expected Volume Impact: None. The grant is not a market transaction and will not affect trading volume.
• Sentiment Indicator: Neutral. This filing is informational and related to executive compensation, not market sentiment.

Additional Context

Transaction Notes

• Vesting Schedule: The options vest in full on the one-year anniversary of the grant date (December 18, 2026), contingent on the director's continued service.
• Exercise Price: The options have an exercise price of $0.5848 per share.